Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
Back to event

Opioid Users Found a ‘Miracle Drug’ to Help Them Quit. Then the DEA Banned It

By Manisha Krishnan · Nov 3, 2026, 4:00 AM CST

Read full article at Wired
On Reddit and Discord, people addicted to opioids say SR-17018 can remove withdrawal symptoms. Despite its potential, the DEA has placed it in the same category as heroin.

Excerpt shown under fair-use limits. Full text remains with the original publisher.

People in this coverage

Explore their history and attributable record. Being mentioned does not imply endorsement.

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation
INSUFFICIENT CONTEXT
Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

Anecdotal AppealThe article relies on unverified personal testimonies from online forums to make a health claim.

Authority ClaimThe statement invokes the DEA to lend weight to the claim, yet provides no official source or documentation.

SensationalismThe headline uses dramatic language ('Miracle Drug', 'Banned') to attract attention without substantiating the claims.

Context

AI analysis

Missing context

The article does not provide scientific studies, clinical trial data, or official DEA documentation to substantiate the efficacy of SR-17018 or its scheduling status. It also lacks information about the drug’s regulatory approval process, safety profile, and the broader context of opioid addiction treatment options.

Important context

Understanding the opioid crisis, the role of the DEA in drug scheduling, and the standards for evaluating new addiction‑treatment compounds are essential for assessing the credibility of the claims made about SR-17018.

Opinion vs. reporting

AI analysis

The piece leans heavily toward opinion and anecdotal reporting, presenting unverified user statements and alleged regulatory actions without corroborating evidence.